Clinical Characteristic and Treatment Options of Patients with G3 Gastroenteropancreatic Neuroendocrine Neoplasms in China Abstract #1444

Introduction: Well differentiated neuroendocrine tumor G3 (NET G3) patients are a special part of neuroendocrine neoplasms with a different biological behavior comparing with other G3 patients.
Aim(s): This study was to investigate the clinical pathological features, the impact of different treatment strategies on their clinical outcomes of NET G3 and neuroendocrine carcinoma (NEC) patients in Chinese populations.
Materials and methods: We retrospectively collected 28 NET G3 patients from oncology departments of three hospitals in China and 38 NEC patients for comparison.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Ru Jia
Keywords: NET G3, NEC, TEMCAP

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1070 Subtype Classification and Clinicopathological Characteristics of 78 Cases with Gastric Neuroendocrine Neoplasms
Introduction: Gastric NENs are a group of neoplasms with diverse clinicopathological features.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: Dr. Huang Ying Tan
Authors: Zhang C, Tan H Y, Liu J X, Luo J, ...
#1666 Prognosis and Incidence in Pancreatic and Gastrointestinal Neuroendocrine Neoplasms with Emphasis on “NET G3”: An Analysis of 198 Cases from Japan
Introduction: Prognostic impact of well differentiated pancreatic neuroendocrine neoplasms (PanNENs) with a Ki67 >20%, provisionally called NET G3, needs to be validated and compared to poorly differentiated neuroendocrine carcinomas (NECs). Moreover, the frequency of NET G3 among gastrointestinal NENs (GI-NENs) has so far not been studied.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Atsuko Kasajima
Keywords: NET G3, GEP-NEN, GI-NET
#1287 Subtype Classification and Clinicopathological Features of Gastric Neuroendocrine Neoplasms: Experiences in 116 Chinese Patients
Introduction: Gastric NEN are a heterogeneous group of tumors.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Dr. Huang Ying Tan
Authors: Zhang P, Zhang C, Luo J, Liu J X, ...
Keywords: gastric nen, type 1
#1564 Well Differentiated Pancreatic Neuroendocrine Tumors (WDPNET) G3: Does the Ki67 Really Do It All?
Introduction: WDPNET G3, although not recognized by the 2010 WHO classification are far from exceptional. They also represent a great therapeutic challenge especially since their molecular drivers are unknown.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Dr Jerome Cros
#979 Characteristics and Treatments of Patients with G3 Gastroenteropancreatic Neuroendocrine Tumors (G3-NET) and Neuroendocrine Carcinoma (NEC): A European Multicenter Retrospective Study
Introduction: Data on G3-NET and NEC are limited. No standard therapy following platinum-etoposide failure is established and first-line therapy in G3-NET is not codified.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Maximilian Heetfeld
Close
Notice
Important Notice:

In preparation of the upcoming ENETS Barcelona 2018 Annual Conference, we have discovered in the world wide web at least one professional entity suggestive of possessing an ENETS mandate for conference registrations. Therefore, we must inform you that 100% of all conference participants are registered through ENETS official website www.enets.org and http://enetsconference.org/. There are no further options to validly register for Barcelona 2018 (or for any other ENETS event).

Please stay away from fraudulent scams abusing the ENETS acronym to register – and charge you above official ENETS conference fees! Such entities, against whom ENETS presses criminal charges, are neither authorized, nor commissioned nor instructed by ENETS to make such representations.